G
Gary M. Clark
Researcher at University of Texas Health Science Center at San Antonio
Publications - 207
Citations - 40397
Gary M. Clark is an academic researcher from University of Texas Health Science Center at San Antonio. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 73, co-authored 205 publications receiving 38991 citations. Previous affiliations of Gary M. Clark include University of Vermont Medical Center.
Papers
More filters
Journal ArticleDOI
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
Dennis J. Slamon,Gary M. Clark,Steven G. Wong,Wendy J. Levin,Axel Ullrich,William L. McGuire +5 more
TL;DR: Amplification of the HER-2/neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer, and had greater prognostic value than most currently used prognostic factors in lymph node-positive disease.
Journal ArticleDOI
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
Malcolm J. Moore,David Goldstein,John T. Hamm,Arie Figer,J. R. Hecht,Steven Gallinger,Heather J. Au,Pawel Murawa,David Walde,Robert A. Wolff,D. M. B. Campos,Robert Lim,Keyue Ding,Gary M. Clark,Theodora Voskoglou-Nomikos,Mieke Ptasynski,Wendy R. Parulekar +16 more
TL;DR: To the authors' knowledge, this randomized phase III trial is the first to demonstrate statistically significantly improved survival in advanced pancreatic cancer by adding any agent to gemcitabine.
Journal Article
Prognostic and predictive factors in breast cancer by immunohistochemical analysis
TL;DR: Although available studies suggest that estrogen and progesterone receptors might indeed be helpful in making treatment decisions, their clinical usefulness is still controversial, and there are important unresolved technical issues, such as how to prepare the tissue, which reagents to use and, most importantly, how to interpret the results.
Journal ArticleDOI
Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer
TL;DR: IHC is superior to the LBA for assessing ER status in primary breast cancer because it is easier, safer, and less expensive, and has an equivalent or better ability to predict response to adjuvant endocrine therapy.
Journal ArticleDOI
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.
Patrick L. Fitzgibbons,David L. Page,Donald L. Weaver,Ann D. Thor,Allred Dc,Gary M. Clark,Stephen G. Ruby,O'Malley F,Simpson Jf,James L. Connolly,Daniel F. Hayes,Stephen B. Edge,Lichter A,Stuart J. Schnitt +13 more
TL;DR: This report constitutes a detailed outline of the findings and recommendations of the consensus conference group, organized according to structural guidelines as defined.